Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand

Aims/hypothesis Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). Me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetologia 2008-06, Vol.51 (6), p.1035-1040
Hauptverfasser: Mabilleau, G, Petrova, N. L, Edmonds, M. E, Sabokbar, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1040
container_issue 6
container_start_page 1035
container_title Diabetologia
container_volume 51
creator Mabilleau, G
Petrova, N. L
Edmonds, M. E
Sabokbar, A
description Aims/hypothesis Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). Methods Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices. Results In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p = 0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p < 0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264 ± 0.06% to 41.6 ± 8.1%, p < 0.0001) and diabetic control (0.000 ± 0.00% to 14.2 ± 16.5%, p < 0.0001) patients, and also in healthy control participants (0.004 ± 0.01% to 10.5 ± 1.9%, p < 0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6 ± 8.1% to 5.9 ± 2.4%, p = 0.001), this suppression was not as complete as in diabetic control patients (14.2 ± 16.5% to 0.45 ± 0.31%, p = 0.001) and in healthy control participants (from 10.5 ± 1.9% to 0.00 ± 0.00%, p < 0.0001). Conclusions/interpretation These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.
doi_str_mv 10.1007/s00125-008-0992-1
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19474146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c557t-99f3d71cfc9f31187e1e5d4a42c09248416bb1ce9eb931105f0af101e9c1e2783</originalsourceid><addsrcrecordid>eNp9kk-L1EAQxYMo7rj6ATwZBBUP0a7uzp_2IKyDugsDHnTBW1PTqUyyZtLZ7s7AXP3kdsiw4h48dVHvV6-K5iXJc2DvgLHyvWcMeJ4xVmVMKZ7Bg2QFUvCMSV49TFaznEFV_DxLnnh_wxgTuSweJ2dQiUpxYKvk99VgHKGnOrU-kDU9-tCZFE3oDl04pt0Q6ylQum7RGRve-AVEF1o7YmiPH9LQUupsT6ltUkeGxmDd4oBzFbvDZHpClzaxa132C8cRP6V9t8Ohfpo8arD39Oz0nifXXz7_WF9mm29fr9YXm8zkeRkypRpRl2AaEwuAqiSgvJYouWGKy0pCsd2CIUVbFXWWNwwbYEDKAPGyEufJx8V3nLZ7qg0NwWGvR9ft0R21xU7_qwxdq3f2oLkoOAgZDd4uBu29scuLjZ57TPAClBIHiOzr0zJnbyfyQe87b6jvcSA7eQ1KlhJkEcGX98AbO7khfoSOSytZgswjBAtknPXeUXO3Hpieo6CXKOgYBT1HQc8XvDoZozfYNw4H0_m7Qc5yVZWVihxfOB-lYUfu7wH_M3-xDDVoNe5cNL7-zhmIyCgoQIg_tH7MzQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213847145</pqid></control><display><type>article</type><title>Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand</title><source>SpringerLink Journals - AutoHoldings</source><creator>Mabilleau, G ; Petrova, N. L ; Edmonds, M. E ; Sabokbar, A</creator><creatorcontrib>Mabilleau, G ; Petrova, N. L ; Edmonds, M. E ; Sabokbar, A</creatorcontrib><description>Aims/hypothesis Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). Methods Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices. Results In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p = 0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p &lt; 0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264 ± 0.06% to 41.6 ± 8.1%, p &lt; 0.0001) and diabetic control (0.000 ± 0.00% to 14.2 ± 16.5%, p &lt; 0.0001) patients, and also in healthy control participants (0.004 ± 0.01% to 10.5 ± 1.9%, p &lt; 0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6 ± 8.1% to 5.9 ± 2.4%, p = 0.001), this suppression was not as complete as in diabetic control patients (14.2 ± 16.5% to 0.45 ± 0.31%, p = 0.001) and in healthy control participants (from 10.5 ± 1.9% to 0.00 ± 0.00%, p &lt; 0.0001). Conclusions/interpretation These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-008-0992-1</identifier><identifier>PMID: 18389210</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Biological and medical sciences ; Charcot's osteoarthropathy ; Diabetes ; Diabetes. Impaired glucose tolerance ; Diseases of the osteoarticular system ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Foot diseases ; Human Physiology ; Internal Medicine ; Life Sciences ; Ligands ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Miscellaneous. Osteoarticular involvement in other diseases ; OPG ; osteoclasts ; Osteolysis ; Pathogenesis ; Phosphatase ; RANKL ; resorption</subject><ispartof>Diabetologia, 2008-06, Vol.51 (6), p.1035-1040</ispartof><rights>Springer-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c557t-99f3d71cfc9f31187e1e5d4a42c09248416bb1ce9eb931105f0af101e9c1e2783</citedby><cites>FETCH-LOGICAL-c557t-99f3d71cfc9f31187e1e5d4a42c09248416bb1ce9eb931105f0af101e9c1e2783</cites><orcidid>0000-0003-1445-329X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00125-008-0992-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00125-008-0992-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20598789$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-angers.hal.science/hal-03261993$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Mabilleau, G</creatorcontrib><creatorcontrib>Petrova, N. L</creatorcontrib><creatorcontrib>Edmonds, M. E</creatorcontrib><creatorcontrib>Sabokbar, A</creatorcontrib><title>Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><description>Aims/hypothesis Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). Methods Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices. Results In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p = 0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p &lt; 0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264 ± 0.06% to 41.6 ± 8.1%, p &lt; 0.0001) and diabetic control (0.000 ± 0.00% to 14.2 ± 16.5%, p &lt; 0.0001) patients, and also in healthy control participants (0.004 ± 0.01% to 10.5 ± 1.9%, p &lt; 0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6 ± 8.1% to 5.9 ± 2.4%, p = 0.001), this suppression was not as complete as in diabetic control patients (14.2 ± 16.5% to 0.45 ± 0.31%, p = 0.001) and in healthy control participants (from 10.5 ± 1.9% to 0.00 ± 0.00%, p &lt; 0.0001). Conclusions/interpretation These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.</description><subject>Biological and medical sciences</subject><subject>Charcot's osteoarthropathy</subject><subject>Diabetes</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diseases of the osteoarticular system</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Foot diseases</subject><subject>Human Physiology</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Miscellaneous. Osteoarticular involvement in other diseases</subject><subject>OPG</subject><subject>osteoclasts</subject><subject>Osteolysis</subject><subject>Pathogenesis</subject><subject>Phosphatase</subject><subject>RANKL</subject><subject>resorption</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kk-L1EAQxYMo7rj6ATwZBBUP0a7uzp_2IKyDugsDHnTBW1PTqUyyZtLZ7s7AXP3kdsiw4h48dVHvV6-K5iXJc2DvgLHyvWcMeJ4xVmVMKZ7Bg2QFUvCMSV49TFaznEFV_DxLnnh_wxgTuSweJ2dQiUpxYKvk99VgHKGnOrU-kDU9-tCZFE3oDl04pt0Q6ylQum7RGRve-AVEF1o7YmiPH9LQUupsT6ltUkeGxmDd4oBzFbvDZHpClzaxa132C8cRP6V9t8Ohfpo8arD39Oz0nifXXz7_WF9mm29fr9YXm8zkeRkypRpRl2AaEwuAqiSgvJYouWGKy0pCsd2CIUVbFXWWNwwbYEDKAPGyEufJx8V3nLZ7qg0NwWGvR9ft0R21xU7_qwxdq3f2oLkoOAgZDd4uBu29scuLjZ57TPAClBIHiOzr0zJnbyfyQe87b6jvcSA7eQ1KlhJkEcGX98AbO7khfoSOSytZgswjBAtknPXeUXO3Hpieo6CXKOgYBT1HQc8XvDoZozfYNw4H0_m7Qc5yVZWVihxfOB-lYUfu7wH_M3-xDDVoNe5cNL7-zhmIyCgoQIg_tH7MzQ</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Mabilleau, G</creator><creator>Petrova, N. L</creator><creator>Edmonds, M. E</creator><creator>Sabokbar, A</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>FBQ</scope><scope>C6C</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QP</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1445-329X</orcidid></search><sort><creationdate>20080601</creationdate><title>Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand</title><author>Mabilleau, G ; Petrova, N. L ; Edmonds, M. E ; Sabokbar, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c557t-99f3d71cfc9f31187e1e5d4a42c09248416bb1ce9eb931105f0af101e9c1e2783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Charcot's osteoarthropathy</topic><topic>Diabetes</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diseases of the osteoarticular system</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Foot diseases</topic><topic>Human Physiology</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Miscellaneous. Osteoarticular involvement in other diseases</topic><topic>OPG</topic><topic>osteoclasts</topic><topic>Osteolysis</topic><topic>Pathogenesis</topic><topic>Phosphatase</topic><topic>RANKL</topic><topic>resorption</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mabilleau, G</creatorcontrib><creatorcontrib>Petrova, N. L</creatorcontrib><creatorcontrib>Edmonds, M. E</creatorcontrib><creatorcontrib>Sabokbar, A</creatorcontrib><collection>AGRIS</collection><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mabilleau, G</au><au>Petrova, N. L</au><au>Edmonds, M. E</au><au>Sabokbar, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand</atitle><jtitle>Diabetologia</jtitle><stitle>Diabetologia</stitle><date>2008-06-01</date><risdate>2008</risdate><volume>51</volume><issue>6</issue><spage>1035</spage><epage>1040</epage><pages>1035-1040</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Aims/hypothesis Our aims were to compare osteoclastic activity between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). Methods Peripheral blood monocytes isolated from nine diabetic Charcot patients, eight diabetic control and eight healthy control participants were cultured in the presence of macrophage-colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and RANKL with excess concentrations of OPG. Osteoclast formation was assessed by expression of tartrate-resistant acid phosphatase on glass coverslips and resorption on dentine slices. Results In cultures with M-CSF, there was a significant increase in osteoclast formation in Charcot patients compared with healthy and diabetic control participants (p = 0.008). A significant increase in bone resorption was also seen in the former, compared with healthy and diabetic control participants (p &lt; 0.0001). The addition of RANKL to the cultures with M-CSF led to marked increase in osteoclastic resorption in Charcot (from 0.264 ± 0.06% to 41.6 ± 8.1%, p &lt; 0.0001) and diabetic control (0.000 ± 0.00% to 14.2 ± 16.5%, p &lt; 0.0001) patients, and also in healthy control participants (0.004 ± 0.01% to 10.5 ± 1.9%, p &lt; 0.0001). Although the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of resorption in Charcot patients (41.6 ± 8.1% to 5.9 ± 2.4%, p = 0.001), this suppression was not as complete as in diabetic control patients (14.2 ± 16.5% to 0.45 ± 0.31%, p = 0.001) and in healthy control participants (from 10.5 ± 1.9% to 0.00 ± 0.00%, p &lt; 0.0001). Conclusions/interpretation These results indicate that RANKL-mediated osteoclastic resorption occurs in acute Charcot's osteoarthropathy. However, the incomplete inhibition of RANKL after addition of OPG also suggests the existence of a RANKL-independent pathway.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18389210</pmid><doi>10.1007/s00125-008-0992-1</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1445-329X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-186X
ispartof Diabetologia, 2008-06, Vol.51 (6), p.1035-1040
issn 0012-186X
1432-0428
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362134
source SpringerLink Journals - AutoHoldings
subjects Biological and medical sciences
Charcot's osteoarthropathy
Diabetes
Diabetes. Impaired glucose tolerance
Diseases of the osteoarticular system
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Foot diseases
Human Physiology
Internal Medicine
Life Sciences
Ligands
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Miscellaneous. Osteoarticular involvement in other diseases
OPG
osteoclasts
Osteolysis
Pathogenesis
Phosphatase
RANKL
resorption
title Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T07%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20osteoclastic%20activity%20in%20acute%20Charcot's%20osteoarthopathy:%20the%20role%20of%20receptor%20activator%20of%20nuclear%20factor-kappaB%20ligand&rft.jtitle=Diabetologia&rft.au=Mabilleau,%20G&rft.date=2008-06-01&rft.volume=51&rft.issue=6&rft.spage=1035&rft.epage=1040&rft.pages=1035-1040&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-008-0992-1&rft_dat=%3Cproquest_pubme%3E19474146%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213847145&rft_id=info:pmid/18389210&rfr_iscdi=true